Candel Therapeutics (NASDAQ:CADL) Insider Francesca Barone Sells 23,447 Shares of Stock

Posted by Brian Himes on Jul 1st, 2026

Candel Therapeutics, Inc. (NASDAQ:CADL – Get Free Report) insider Francesca Barone sold 23,447 shares of the company’s stock in a transaction that occurred on Monday, June 29th. The shares were sold at an average price of $10.06, for a total value of $235,876.82. Following the completion of the transaction, the insider directly owned 77,362 shares in the company, valued at approximately $778,261.72. The trade was a 23.26% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Candel Therapeutics Stock Down 4.1%

Shares of Candel Therapeutics stock traded down $0.42 on Wednesday, hitting $9.88. 1,870,682 shares of the company’s stock traded hands, compared to its average volume of 1,599,176. Candel Therapeutics, Inc. has a 52-week low of $4.35 and a 52-week high of $11.36. The company has a quick ratio of 28.05, a current ratio of 28.05 and a debt-to-equity ratio of 0.34. The stock has a market cap of $723.91 million, a P/E ratio of -10.08 and a beta of -0.49. The firm’s 50-day moving average is $8.19 and its 200 day moving average is $6.43.

Candel Therapeutics (NASDAQ:CADL – Get Free Report) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.16. Equities analysts anticipate that Candel Therapeutics, Inc. will post -0.97 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on CADL. Canaccord Genuity Group reaffirmed a “buy” rating and set a $25.00 price target on shares of Candel Therapeutics in a research report on Friday, March 13th. Zacks Research upgraded Candel Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, May 15th. Wall Street Zen upgraded Candel Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, June 1st. Citigroup dropped their price target on Candel Therapeutics from $24.00 to $22.00 and set a “buy” rating on the stock in a research report on Friday, March 13th. Finally, Cantor Fitzgerald began coverage on shares of Candel Therapeutics in a report on Monday, April 20th. They issued an “overweight” rating for the company. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $18.00.

View Our Latest Analysis on Candel Therapeutics

Institutional Investors Weigh In On Candel Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC acquired a new position in shares of Candel Therapeutics during the first quarter valued at $845,000. Renaissance Technologies LLC acquired a new position in Candel Therapeutics during the 1st quarter valued at about $63,000. AlphaCentric Advisors LLC acquired a new position in Candel Therapeutics during the 1st quarter valued at about $178,000. Bank of New York Mellon Corp grew its position in Candel Therapeutics by 43.1% in the 1st quarter. Bank of New York Mellon Corp now owns 136,266 shares of the company’s stock worth $668,000 after purchasing an additional 41,058 shares during the last quarter. Finally, Halter Ferguson Financial Inc. increased its stake in shares of Candel Therapeutics by 20.9% in the first quarter. Halter Ferguson Financial Inc. now owns 904,051 shares of the company’s stock valued at $4,430,000 after purchasing an additional 155,996 shares during the period. 13.93% of the stock is currently owned by institutional investors.

Candel Therapeutics Company Profile

(Get Free Report)

Candel Therapeutics (NASDAQ:CADL) is a clinical-stage immuno-oncology company focused on the development of next-generation oncolytic viral therapies designed to treat solid tumors. The company’s lead candidate, CAN-2409, is a locally administered, gene-delivered viral therapy engineered to selectively replicate in cancer cells and induce immunogenic cell death. Candel leverages proprietary virus engineering platforms to enhance tumor-specific replication and stimulate anti-tumor immune responses, aiming to improve outcomes for patients with high unmet medical needs.

In addition to its lead program, Candel’s pipeline includes CAN-3110, an oncolytic herpes simplex virus targeting recurrent high-grade glioma, and other novel viral constructs being explored for a variety of solid tumor indications.